Page 67 - 77_04

G.
LOLLO
ET
AL.

51.
Nune,
S.K.,
&
al.
(2011).
Advances
in
lymphatic
imaging
&
drug
delivery.
Advanced
Drug

Delivery
Reviews,
63(10-­-11),

876-­-885.

52.
Hu,
Y.-­-L.,
&
al.
(2010).
J
Mesenchymal
stem
cells:
A
promising
targeted-­-delivery
vehicle
in

cancer
gene
therapy.
ournal
of
Controlled
Release,
147(2),

154-­-162.

53.
Rochlitz,
C.F.
(2001).
Gene
therapy
of
cancer.
SWISS
MED
WKLY,
131,

4-­-9.

54.
Jeong,
J.H.,
&
al.
(2011)
Self-­-Assembled
&
Nanostructured
siRNA
Delivery
Systems.

Pharmaceutical
Research,
28(9),

2072-­-2085.

55.
Bedikian,
A.Y.,
&
al.
(2008).
Allovectin-­-7
therapy
in
metastatic
melanoma.
Expert
Opinion
on

Biological
Therapy,

8(6),

839-­-844.

56.
Bedikian,
A.Y.,
&
al.
(2010).
A
phase
2
study
of
high-­-dose
Allovectin-­-7
in
patients
with

advanced
metastatic
melanoma.
Melanoma
Research,
20(3),

218-­-226.

57.
Study
With
Atu027
in
Patients
With
Advanced
Solid
Cancer.
(2011)

http://clinicaltrials.gov/ct2/show/NCT00938574?term=atu+027&rank=1.

58.
Aleku,
M.,
&
al.
(2008).
Atu027,
a
Liposomal
Small
Interfering
RNA
Formulation
Targeting

Protein
Kinase
N3,
Inhibits
Cancer
Progression.
Cancer
Research,

68(23),

9788-­-9798.

59.
Davis,
M.E.
(2009).
The
First
Targeted
Delivery
of
siRNA
in
Humans
via
a
Self-­-Assembling,

Cyclodextrin
Polymer-­-Based
Nanoparticle:
From
Concept
to
Clinic.
Molecular
Pharmaceutics,

6(3),

659-­-668.

60.
Morikawa,
T.,
&
al.
(2010).
Expression
of
ribonucleotide
reductase
M2
subunit
in
gastric
cancer

&
effects
of
RRM2
inhibition
in
vitro.
Human
Pathology,
41(12),

1742-­-1748.

61.
O'Hagan,
D.T.,
&
al.
(2006).
Novel
approaches
to
pediatric
vaccine
delivery.
Advanced
Drug

Delivery
Reviews,
58(1),

29-­-51.

62.
Vicente,
S.,
&
al.
(2009).
Nanovacunas,
in
Nanotecnología
Farmacéutica:
Realidades
y

posibilidades
farmacoterapéuticas,
J.L.
Vila-­-Jato,
Editor,
Instituto
de
España,
Real
Academia

Nacional
de
Farmacia:
Madrid,
España.

320.

63.
Shurin,
M.R.,
&
al.
(2011).
Regulatory
dendritic
cells
New
targets
for
cancer
immunotherapy.

Cancer
Biology
&
Therapy,
11(11),

988-­-992.

64.
Sangha,
R.,
&
al.
(2007).
L-­-BLP25,
A
Peptide
Vaccine
Strategy
in
Non–Small
Cell
Lung
Cancer.

Clinical
Cancer
Research,
13(15),

4652s-­-4654s.

65.
Pene,
F.,
&
al.
(2009).
Toward
theragnostics.
Critical
Care
Medicine,
37(1),

S50-­-S58

10.1097/CCM.0b013e3181921349.

66.
Kievit,
F.M.,
&
al.
(2011).
Cancer
Nanotheranostics:
Improving
Imaging
&
Therapy
by
Targeted

Delivery
Across
Biological
Barriers.
Advanced
Materials,
23(36),

H217-­-H247.

67.
Lammers,
T.,
&
al.
(2010).
Nanotheranostics
&
Image-­-Guided
Drug
Delivery:
Current
Concepts

&
Future
Directions.
Molecular
Pharmaceutics,
7(6),

1899-­-1912.

98